Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:

Pilot Phase II Study to Evaluate Effect of Cetuximab Given as Single Agent After Immunotherapy With PD-1 Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04375384
• Other study ID #: IRB00065239
• Secondary ID: WFBCCC 60220P30C
• Status: Recruiting
• Phase: Phase 2
• Start date: July 1, 2020
• Est. completion date: January 2025

Study information

• Verified date: April 2024
• Source: Wake Forest University Health Sciences
• Contact: Study Nurse
• Phone: 336-713-7748
• Email: saverill[@]wakehealth.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.

Description:

Primary Objective:

• To measure Overall Response Rate to treatment with Cetuximab as single agent in patients with recurrent or metastatic head and neck squamous cell cancer who failed PD-1 inhibitors alone or in combination with chemotherapy.

Secondary Objective(s):

• Measure Duration of Response (DUR), Progression Free Survival and Overall Survival and for treatment with single agent Cetuximab after immunotherapy with PD-1 inhibitors in Head and Neck Squamous Cell Carcinoma.

• Evaluate treatment toxicity with single agent Cetuximab in this patient population.

OUTLINE: Patients receive cetuximab intravenously (IV) over 60-120 minutes once every week in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 week and then every 6-8 weeks thereafter.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2025
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed head and neck squamous cell carcinoma.

• Measurable disease by scans- at least one measurable lesion.

• Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy.

• Patients must have a Performance Status of 0-2.

• Patients must be greater than or equal to 18 years old.

• Willing to provide consent for collection of samples of blood and saliva as scheduled through the treatment.

• Subject is willing and able to comply with the protocol for the duration of the study.

• Willingness to donate 2 tablespoons of blood and one teaspoon of saliva for research before treatment, 3 more times during the first 5 weeks of treatment and then at cancer progression.

• Ability to understand and the willingness to sign an Institutional Review Board-approved informed consent document.

Exclusion Criteria:

• Prior treatment with Cetuximab or prior therapy that specifically and directly targets the epidermal growth factor receptor (EGFR) pathway.

• Prior allergic reaction to Cetuximab.

• History of allergic reactions attributed to compounds of chemical or biologic composition similar to those of Cetuximab.

• Patients receiving any other investigational agents.

• Patient is on medications that need to be continued and that might interact with Cetuximab.

• Any uncontrolled condition, which in the opinion of the investigator, would interfere in the safe and timely completion of study treatment and procedures.

• Subject with a history of interstitial lung disease (e.g. pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on screening chest imaging.

Any of the following conditions:

• Serious or non-healing wound, ulcer, or bone fracture at the discretion of treating physician

• history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of study enrollment

• history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study enrollment

• history of myocardial infarction, ventricular arrhythmia, stable/unstable angina, -symptomatic congestive heart failure, coronary/peripheral artery bypass graft or stenting or other significant cardiac disease within 6 months prior to study enrollment

• history of arterial or venous thrombosis/thromboembolic event, including pulmonary embolism within 6 months of study enrollment

• any condition requiring the use of immunosuppression, excluding rheumatologic conditions treated with stable doses of corticosteroids.

Pregnancy, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Carcinoma
• Metastatic Head-and-neck Squamous-cell Carcinoma
• Recurrent Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• Cetuximab
A loading dose of Cetuximab will be administered intravenously in the first day of treatment. The dose is 400 mg/m2 and will be infused over 2h followed by 1h observation. The maintenance dose of Cetuximab is 250 mg/m2 and will be infused over 1h. No further observation time needed. The maintenance dose of cetuximab will be given every 7 days (+/- 2 days) starting 7 days (+/- 2 days) after the loading dose of cetuximab. Pre-medicate with 50 mg Diphenhydramine IV before the loading dose of Cetuximab and as per standard of care before the maintenance treatment.

Other:
• Questionnaire administration
Ancillary studies
• Quality of life assessment
Ancillary studies

Locations

Country	Name	City	State
United States	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Overall Response Rate To Treatment with Cetuximab	Response to treatment with Cetuximab as a single agent following treatment with immunotherapy with PD-1 inhibitors alone or in combination with chemotherapy will be assessed with imaging studies. Overall response rate is defined as the proportion patients achieving partial response or complete response per RECIST v1.1 criteria. An estimate of a 95% Exact Clopper Pearson confidence interval will be used. RECIST 1.1 criteria will be used to measure tumor size: Measurable disease is defined by the presence of at least 1 measurable lesion. A lesion, not previously irradiated per the protocol prior to enrollment, that can be accurately measured at baseline as =10 mm in the longest diameter (except lymph nodes which must have short axis =15 mm) with CT or MRI and that is suitable for accurate repeated measurements. Non-measurable: All other lesions, including small lesions (longest diameter <10 mm or pathological lymph nodes with =10 mm to <15 mm short axis at baseline).	14 days before start of treatment, 7 weeks after start of treatment, and then every 6-8 weeks for the duration of treatment, up to approximately 2 years.
Secondary	Duration of Progression Free Survival	Progression free survival will be defined as progression of local-regional disease, distant metastases or death without progression and will be reported as median progression-free survival as well as progression free survival at 6 month and 1 year time points. Investigators will estimate Kaplan Meier survival curves and estimate the median duration of response with 95% confidence intervals for these measures.	At 6 months and at 1 year after enrollment on study
Secondary	Duration of Overall Survival	Overall survival is defined as death due to any cause and will be reported as median overall survival as well as overall survival at 6 month and 1 year time points. Investigators will estimate Kaplan Meier survival curves and estimate the median duration of response with 95% confidence intervals for these measures.	At 6 months and at 1 year after enrollment on study
Secondary	Number of Treatment-Related Toxicities with Cetuximab as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Treatment-related side effects will be collected before each treatment based on clinical laboratory and radiologic changes and will be graded and reported. All patients who receive at least one dose of cetuximab will be considered evaluable for safety analysis. Investigators will create frequency tables that count the number and severity of toxicities observed in this study.	Up to 2 years